Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy

Prof David Ferry - New Cross Hospital, Wolverhampton, UK
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy ( Prof David Ferry - New Cross Hospital, Wolverhampton, UK )
29 Sep 2012

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Dr Tony Mok - Chinese University of Hong Kong
Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib ( Dr Tony Mok - Chinese University of Hong Kong )
29 Sep 2012

Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial

Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer – Phase III MISSION trial ( Dr Luis Paz-Ares - Virgen del Rocio University Hospital in Seville, Spain )
29 Sep 2012

iwNHL 10: Advances in the treatment of lymphoma

Dr Wyndham Wilson - National Cancer Institute, Bethesda, MD, USA; Dr Myron Czuczman - Roswell Park Cancer Institute, Buffalo, NY, USA; Professor Michael Pfreundschuh - University of Saarland, Homburg-Saar, Germany; Prof John Gribben - Bart’s and Royal
iwNHL 10: Advances in the treatment of lymphoma ( Dr Wyndham Wilson - National Cancer Institute, Bethesda, MD, USA; Dr Myron Czuczman - Roswell Park Cancer Institute, Buffalo, NY, USA; Professor Michael Pfreundschuh - University of Saarland, Homburg-Saar, Germany; Prof John Gribben - Bart’s and Royal )
26 Sep 2012

Cost effective care and the state of oncology in India

Dr Rajendra Badwe – Tata Memorial Hospital, Mumbai, India
Cost effective care and the state of oncology in India ( Dr Rajendra Badwe – Tata Memorial Hospital, Mumbai, India )
23 Jul 2012

International Network of bio-banks and expert centres

Prof Kurt Zatloukal – Institute of Pathology, Medical University of Graz, Austria
International Network of bio-banks and expert centres ( Prof Kurt Zatloukal – Institute of Pathology, Medical University of Graz, Austria )
23 Jul 2012

Patient's perspective and regulation of treatments

Jean Mossman – Cancer Charity Consultant
Patient's perspective and regulation of treatments ( Jean Mossman – Cancer Charity Consultant )
20 Jul 2012

The ceRNA Hypothesis and the non-coding revolution in cancer research and therapy

Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA
The ceRNA Hypothesis and the non-coding revolution in cancer research and therapy ( Prof Pier Paolo Pandolfi - Harvard Medical School, Boston, USA )
19 Jul 2012

Underlying metabolic pathways in cancer

Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain
Underlying metabolic pathways in cancer ( Dr Arkaitz Carracedo – Ikerbasque, Bilbao, Spain )
18 Jul 2012

Potential for micro-RNA based cancer treatments

Prof Carlo Croce – Ohio State University, Columbus, USA
Potential for micro-RNA based cancer treatments ( Prof Carlo Croce – Ohio State University, Columbus, USA )
18 Jul 2012

Bevacizumab benefits beyond progression in TML study subgroups

Dr Thierry André – Hôpital Saint Antoine, Paris, France
Bevacizumab benefits beyond progression in TML study subgroups ( Dr Thierry André – Hôpital Saint Antoine, Paris, France )
17 Jul 2012

Translational and tailored, but can we afford it?

Prof Gordon McVie - European Institute of Oncology and ecancer
Translational and tailored, but can we afford it? ( Prof Gordon McVie - European Institute of Oncology and ecancer )
17 Jul 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation